Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Cell Therapeutics Submits MAA to EMA

November 2, 2010 8:48 am | News | Comments

Cell Therapeutics, Inc. announced that it has submitted a marketing authorization application to the European Medicines Agency for Pixuvri for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin's lymphoma.


FDA Grants CF Drug Orphan Drug Status

November 2, 2010 8:37 am | News | Comments

Discovery Laboratories, Inc. announced that the Food and Drug Administration has granted orphan drug designation to Discovery's KL4 surfactant for the treatment of cystic fibrosis.


NuPathe Submits Zelrix NDA

November 2, 2010 8:34 am | News | Comments

NuPathe Inc. announced that the company submitted a New Drug Application for Zelrix to the U.S. Food and Drug Administration. Zelrix is the first ever submission to the FDA of a transdermal patch for the treatment of migraine.


XOMA Discussing Botulinum Toxin Treatment

November 2, 2010 8:29 am | News | Comments

XOMA Ltd announced several presentations that will highlight advances in the company's biodefense program and particularly in the development of XOMA 3AB, an antibody co-mixture that binds to distinct regions of botulinum toxin type A.


Hyperion UCD Drug Succeeds in Phase 3 Study

November 2, 2010 8:21 am | News | Comments

Hyperion Therapeutics, Inc. announced that the company’s phase 3 pivotal study of glycerol phenylbutyrate (HPN-100), an investigational drug for the treatment of urea cycle disorders, met its primary endpoint.


Antisense Publishes Phase 2b Trial Results

November 2, 2010 8:17 am | News | Comments

The investigated drug trabedersen (AP 12009) is a gene silencing antisense compound – a phosphorothioate oligodeoxynucleotide – designed to selectively downregulate the production of transforming growth factor-beta 2 (TGF-?2) at the translational level.


NIR Camera

November 2, 2010 7:50 am | Drug Discovery & Development | Product Releases | Comments

Photometrics, a designer and manufacturer of high-performance CCD and EMCCD cameras for the life sciences, has exclusively integrated eXcelon sensor technology in its Evolve 512 and 128 EMCCD cameras.


CNV Platform

November 2, 2010 7:43 am | Product Releases | Comments

NanoString Technologies, Inc. announced the launch of a novel solution for detecting genetic copy number variations associated with disease susceptibility, drug response, and cancer progression.


Horizon and Mirna Collaborating on miRNA Mimics

November 2, 2010 7:30 am | News | Comments

Horizon Discovery and Mirna Therapeutics announced that they have entered into a collaboration agreement to test the impact of Mirna’s proprietary miRNA mimics on a panel of Horizon’s patient-relevant human isogenic cancer cell models.


RecipharmCobra Eligible for R & D Tax Credits

November 2, 2010 7:17 am | News | Comments

RecipharmCobra Biologics, an international manufacturer of biopharmaceuticals, announces that the French Ministry for Higher Education and Research has recognised RecipharmCobra as an approved research and development service provider.


Lung Cancer Requires Personalized Treatment

November 2, 2010 7:11 am | News | Comments

Rather than a “one-size-fits-all” treatment plan, researchers say lung cancer patients should receive care based on their specific diagnosis, individual genetic makeup and particular tumors.


Omega-3 Fails Memory Test

November 2, 2010 7:05 am | by Lindsay Tanner | News | Comments

Omega-3 pills promoted as boosting memory didn't slow mental and physical decline in older patients with Alzheimer's disease, a big disappointment in a multimillion-dollar government-funded study.


FDA Approves Afinitor

November 2, 2010 7:01 am | News | Comments

The Food and Drug Administration said it approved Novartis' drug Afinitor to treat some of the tumors caused by a rare genetic disorder called tuberous sclerosis.


Pfizer Profits Plummet 70% on Wyeth Charges

November 2, 2010 6:59 am | News | Comments

Pharmaceutical giant Pfizer Inc. said that revenue in the third quarter jumped 39 percent due to its acquisition of fellow drugmaker Wyeth, but hefty charges related to that $68 billion purchase dragged its profit down 70 percent.


Single-cell Analysis Kits

November 1, 2010 8:46 am | Product Releases | Comments

Rubicon Genomics reported data demonstrating that its PicoPlex kits currently marketed for the analysis of single cells for research and diagnostic applications also provide important advantages for genetic and epigenetic profiling using next-generation sequencing.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.